Sara Obringer
Psychiatric/Mental Health · Mc Murray, PANPI 1376301465
Payments from drug & device makers
Across 251 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$702
- AbbVie$657
- Neurocrine Biosciences, Inc.$636
- Teva Pharmaceuticals USA, Inc.$529
- Vanda Pharmaceuticals Inc.$371
- Alkermes, Inc.$347
- plus $752 from 7 others
What the payments were for
- Food & beverage$3,83796%
- Education$1564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 51 | $702 |
| AbbVie | 39 | $657 |
| Neurocrine Biosciences, Inc. | 44 | $636 |
| Teva Pharmaceuticals USA, Inc. | 23 | $529 |
| Vanda Pharmaceuticals Inc. | 29 | $371 |
| Alkermes, Inc. | 15 | $347 |
| Johnson & Johnson | 15 | $267 |
| Lundbeck LLC | 19 | $189 |
| E.r. Squibb & Sons, L.L.C. | 6 | $137 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Corium, LLC | 3 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
How this compares
$3,993 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 18 | $1,762 |
| Lamotrigine | 15 | $465 |
| Quetiapine Fumarate | 17 | $413 |
| Fluoxetine Hcl | 19 | $383 |
| Olanzapine | 11 | $333 |
| Risperidone | 25 | $277 |
| Sertraline Hcl | 24 | $187 |
| Lorazepam | 19 | $123 |
| Trazodone Hcl | 19 | $101 |
| Clonazepam | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Mc Murray
- Amanda HillenMc Murray$17K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.